Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

Emerging Therapies in Differentiated Thyroid Cancer

October 26th 2018

Precision Medicine in Differentiated Thyroid Cancer

October 26th 2018

Differentiated Thyroid Cancer: Sequencing of MTK Inhibitors

October 26th 2018

RAI-Refractory Differentiated Thyroid Cancer: Lenvatinib

October 26th 2018

Practical Considerations for Treating With Sorafenib

October 26th 2018

RAI-Refractory Differentiated Thyroid Cancer: Sorafenib

October 26th 2018

The RIFTOS MKI Study in Differentiated Thyroid Cancer

October 26th 2018

Systemic Therapy for Differentiated Thyroid Cancer

October 26th 2018

Differentiated Thyroid Cancer: RAI Failure and Survival

October 26th 2018

Differentiated Thyroid Cancer: Risk Stratification

October 26th 2018

Approaching RAI-Refractory Differentiated Thyroid Cancer

October 26th 2018

Radioactive Iodine for Differentiated Thyroid Cancer

October 26th 2018

Surgery for Differentiated Thyroid Cancer

October 26th 2018

Expert Management of Differentiated Thyroid Cancer

October 26th 2018

Recommendations for Molecular Testing in Thyroid Cancer

October 26th 2018

Role of Surgery in Diagnosing Thyroid Cancer

October 26th 2018

Considerations in the Diagnosis of Thyroid Cancer

October 26th 2018

Expert Anticipates Bright Future for Immunotherapy in HNSCC

October 25th 2018

Ezra Cohen, MD, discusses the future role of immunotherapy in the treatment of patients with head and neck squamous cell carcinoma.

Dr. Burtness on Findings of KEYNOTE-048 in Head and Neck Cancer

October 22nd 2018

Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses findings from the KEYNOTE-048 in head and neck squamous cell carcinoma (HNSCC).

Cisplatin Remains Standard for Low-Risk HPV+ Oropharyngeal Cancer

October 22nd 2018

Cisplatin plus radiotherapy results in better overall survival and the same rate of all-grade toxicity compared with cetuximab plus radiotherapy in patients with HPV-positive oropharyngeal cancer.